Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2-Low Breast Carcinoma | Phase 3 | - | - | |
HER2-Low Gastric Cancer | Phase 3 | - | - | |
HER2 Positive Solid Tumors | Phase 1 | CN | 23 Nov 2022 | |
HER2 mutant non-small cell lung cancer | IND Approval | CN | 12 Oct 2024 | |
Breast Cancer | Preclinical | CN | 25 Feb 2022 | |
Stomach Cancer | Preclinical | CN | 25 Feb 2022 |
NCT06154343 (ESMO2024) Manual | Phase 1 | 165 | (dyurnibnfo) = jqbhziqdvd nkirthhest (cjhjpkywnt ) View more | Positive | 14 Sep 2024 | ||
(HER2 low BC) | (dyurnibnfo) = kdaputcnna nkirthhest (cjhjpkywnt, 6.1 - NA) View more | ||||||
NCT06154343 (AACR2024) Manual | Phase 1 | 46 | (ixzzxsdzlj) = ojztmylsgp ouptosaybx (ncuoyavbdu ) View more | Positive | 05 Apr 2024 |